URGENT: The COVID-19 epidemic is severely impacting the progress of ALS research at the ALS Therapy Development Institute. If you are able to give, will you please provide an immediate gift to fund our lab?



NP001 may lower the levels of activated cytotoxic macrophages in people with ALS, reducing inflammation and further injury to the motor nerves.


Type: Small Molecule
Stage: Phase II
Status: Completed
Sponsor: Neuraltus Pharmaceuticals

TDI Says:

NP001 failed to meet endpoints in a phase II clinical trial. But a post hoc analysis suggested evidence of potential benefit in a small subset of people with ALS. We are hopeful that the upcoming phase III trial will be designed and powered in a way that enables assessment of efficacy. However, we continue to urge caution in the reliance on historical controls and post hoc analysis alone to support advancement of any drug through the clinical trial process.

Learn More

  • NP001, a quiet riot for ALS?

    CPMC's Forbes Norris ALS Clinic Director Bob Miller MD talks NP001 and its potential for people with ALS going forward.

  • ALS/MND 2012: Trials and tribulations

    Emerging ALS medicines show promise. But key challenges remain to bring them forward to the ALS clinic according to new studies unveiled at ALS MND Chicago.

  • Symphony in M

    Methodist Neurological Institute’s Stanley Appel MD talks about the emerging role of cytotoxic microglia in ALS and potential treatment strategies to combat them looking forward.

Comment on this Topic

(All comments are moderated before they appear here.)